IN8bio Reports No New Deaths or Relapses in Phase 1 Trial of Gamma-Delta T Cell Therapy
IN8bio Reports No New Deaths or Relapses in Phase 1 Trial of Gamma-Delta T Cell Therapy
IN8bio報告在伽馬-德爾塔t電芯治療的第一階段試驗中未出現新死亡或復發。
IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced updated data from the ongoing Phase 1 trial of INB-100, an allogeneic, haploidentical gamma-delta T cell therapy in older patients with hematologic malignancies undergoing haploidentical stem cell transplant (HSCT) with reduced intensity conditioning (RIC) at the 2024 American Society of Hematology (ASH) Annual Meeting, being hosted in San Diego, CA.
In8bio, Inc.（納斯達克：INAB）是一家臨床階段的生物製藥公司，正在開發創新的gamma-delta電芯療法，今天在2024年美國血液學會（ASH）年會上宣佈了關於INb-100的最新數據。該治療是一種全基因相合的gamma-delta電芯療法，針對正在接受減輕強度預處理（RIC）的基因相合的幹細胞移植（HSCT）的老年血液惡性腫瘤患者，會議將在加利福尼亞州聖地亞哥舉行。
資訊熱榜
更新時間